Palvella Therapeutics (PVLA) Current Deferred Revenue (2013 - 2023)
Palvella Therapeutics (PVLA) posted quarterly Current Deferred Revenue of $3.5 million for Q3 2023, up 400.0% year-over-year from $700000.0 in Q3 2022, and down 25.53% quarter-over-quarter from $4.7 million in Q2 2023.
Palvella Therapeutics (PVLA) Current Deferred Revenue (2013 - 2023) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Current Deferred Revenue for 9 consecutive years, with $3.5 million the latest figure, recorded in Q3 2023.
- In Q3 2023, Current Deferred Revenue rose 400.0% year-over-year to $3.5 million; the TTM figure through Sep 2023 stood at $3.5 million (up 400.0% YoY), while the FY2022 annual figure was $20.8 million, down 17.09% from the prior year.
- Current Deferred Revenue slipped to $3.5 million in Q3 2023 per PVLA's latest filing, from $4.7 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $28.4 million in Q2 2019 and bottomed at $700000.0 in Q3 2022.
- Historically, Current Deferred Revenue has averaged $17.4 million across 5 years, with a median of $20.8 million in 2022.
- Annual changes were most pronounced in 2022 — Current Deferred Revenue plunged 97.35% — and 2023, when it surged 400.0%.
- Palvella Therapeutics' Current Deferred Revenue stood at $11.3 million in 2019, then grew by 12.18% to $12.6 million in 2020, then surged by 98.91% to $25.1 million in 2021, then declined by 17.09% to $20.8 million in 2022, then sank by 83.19% to $3.5 million in 2023.
- Business Quant data shows PVLA's Current Deferred Revenue at $3.5 million in Q3 2023, $4.7 million in Q2 2023, and $26.7 million in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Palvella Therapeutics | 2.25 Bn | 1.93 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 3.50 Mn |
| Jun 30, 2023 | 4.70 Mn |
| Mar 31, 2023 | 26.69 Mn |
| Dec 31, 2022 | 20.82 Mn |
| Sep 30, 2022 | 700,000.00 |
| Jun 30, 2022 | 22.86 Mn |
| Mar 31, 2022 | 20.91 Mn |
| Dec 31, 2021 | 25.12 Mn |
| Sep 30, 2021 | 26.45 Mn |
| Jun 30, 2021 | 25.54 Mn |
| Mar 31, 2021 | 17.24 Mn |
| Dec 31, 2020 | 12.63 Mn |
| Sep 30, 2020 | 10.05 Mn |
| Jun 30, 2020 | 7.91 Mn |
| Mar 31, 2020 | 10.04 Mn |
| Dec 31, 2019 | 11.26 Mn |
| Sep 30, 2019 | 27.24 Mn |
| Jun 30, 2019 | 28.41 Mn |
| Mar 31, 2019 | 28.18 Mn |
| Dec 31, 2018 | 35.61 Mn |